MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease with a very poor prognosis. At the same time, its incidence is on the rise, and PDAC is expected to become the second leading cause of cancer-related death by 2030. Despite extensive work on new therapeutic approaches, the median...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2019-01-01
|
| Серія: | Stem Cells International |
| Онлайн доступ: | http://dx.doi.org/10.1155/2019/8475389 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|